Dyne Therapeutics (DYN)

• Market cap: $2.94B
• 1 day: 4.27%
• 5 days: -1.97%
• 1 month: -11.95%
• 3 months: -31.90%
• 6 months: 10.18%
• Year to date: 124.58%
• 1 year: 237.13%
• 5 years: 22.72%
• 10 years: 22.72%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Employees: 152

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

527% more call options, than puts

Call options by funds: $6.11M | Put options by funds: $973K

118% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 22

70% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 46

44% more capital invested

Capital invested by funds: $2.76B [Q1] → $3.96B (+$1.2B) [Q2]

40% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 14 (+4) [Q2]

15% more funds holding

Funds holding: 168 [Q1] → 194 (+26) [Q2]

3.96% less ownership

Funds ownership: 118.67% [Q1] → 114.7% (-3.96%) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 19% upside
• Avg. target: $53 80% upside
• High target: $66 125% upside

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

JP Morgan Tessa Romero 55% 1-year accuracy 11 / 20 met price target	19% upside $35	Neutral Downgraded	24 Oct 2024
Piper Sandler Edward Tenthoff 36% 1-year accuracy 10 / 28 met price target	81% upside $53	Overweight Reiterated	23 Sept 2024
HC Wainwright & Co. Andrew Fein 58% 1-year accuracy 92 / 158 met price target	88% upside $55	Buy Reiterated	4 Sept 2024
Oppenheimer Francois Brisebois 73% 1-year accuracy 22 / 30 met price target	88% upside $55	Outperform Reiterated	3 Sept 2024
Stifel Paul Matteis 43% 1-year accuracy 6 / 14 met price target	125% upside $66	Buy Maintained	16 Aug 2024